Palvella Therapeutics (NASDAQ:PVLA) Trading Down 7.9% – Should You Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) traded down 7.9% during mid-day trading on Wednesday . The stock traded as low as $140.95 and last traded at $140.71. 103,392 shares traded hands during trading, a decline of 64% from the average daily volume of 286,451 shares. The stock had previously closed at $152.82.

Analyst Ratings Changes

A number of equities research analysts have commented on PVLA shares. Stephens reissued an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday. HC Wainwright upped their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Chardan Capital reissued a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Up 6.1%

The firm has a fifty day moving average of $120.35 and a 200-day moving average of $111.68. The firm has a market cap of $2.10 billion, a P/E ratio of -35.19 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC lifted its stake in shares of Palvella Therapeutics by 15.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock valued at $51,556,000 after purchasing an additional 107,937 shares during the period. First Light Asset Management LLC acquired a new stake in shares of Palvella Therapeutics during the third quarter worth $33,949,000. Apis Capital Advisors LLC acquired a new stake in shares of Palvella Therapeutics during the third quarter worth $627,000. Jennison Associates LLC grew its stake in shares of Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after purchasing an additional 280,573 shares during the period. Finally, Fred Alger Management LLC increased its holdings in Palvella Therapeutics by 1,279.1% in the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after purchasing an additional 173,209 shares during the last quarter. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.